Psoriasis and erectile dysfunction may appear to involve unrelated organs, but both can reflect changes in inflammation, blood-vessel function, metabolism, and psychological health. Psoriasis is now understood as a chronic immune-mediated systemic disease rather than a skin-limited condition. Erectile function, meanwhile, depends on healthy endothelial signaling and reliable blood flow. When erection problems develop in a man with psoriasis, the symptom deserves a broader clinical assessment rather than being dismissed as an inevitable consequence of age or stress.
Psoriasis and Erectile Dysfunction: What the Evidence Shows
The association has been observed in population studies, clinical cohorts, and meta-analyses. A 2019 systematic review and meta-analysis combined eight studies involving 39,490 people with psoriasis and nearly 1.8 million participants overall. Psoriasis was associated with higher odds of erectile dysfunction, with a pooled odds ratio of 1.62. After adjustment for measured confounders, the association remained significant, with an odds ratio of 1.50 [1]. These figures describe an association, not proof that psoriasis directly causes ED in every affected man.
A large Danish study reached a similar, more modest conclusion. Among male adults, erectile dysfunction was recorded in 12.8% of those with psoriasis. After statistical adjustment, psoriasis was associated with a 15% increase in the odds of ED and a 14% increase in subsequent risk [2]. The difference between effect sizes is unsurprising: studies use different populations, definitions, and methods for detecting sexual symptoms.
More recent evidence adds nuance. In a 2024 survey using the International Index of Erectile Function, men with psoriasis did not uniformly meet criteria for erectile dysfunction, but they reported significantly lower overall sexual satisfaction and less confidence in maintaining an erection than controls. Longer psoriasis duration also correlated with worse elements of male sexual function [3]. A 2025 clinical review concluded that the connection likely involves interacting vascular, immune, endocrine, neurologic, medication-related, and psychological pathways rather than a single mechanism [4].
These findings should be interpreted carefully. Much of the evidence is observational, erectile dysfunction is measured inconsistently, and cardiovascular or metabolic conditions can influence both diseases. Still, the consistency across study designs makes the association clinically relevant enough to justify screening.
How Systemic Inflammation Can Affect Erections
An erection begins with neural stimulation and the release of nitric oxide in penile tissue. Nitric oxide activates cyclic guanosine monophosphate, or cGMP, which relaxes smooth muscle in the corpora cavernosa. Arterial inflow increases, venous outflow becomes restricted, and rigidity develops. This sequence depends on an endothelium—the cell layer lining blood vessels—that can respond appropriately.
Psoriasis is associated with persistent immune activation involving signaling molecules such as tumor necrosis factor alpha, interleukin-17, and interleukin-23. Chronic inflammatory signaling can promote oxidative stress, reduce nitric oxide availability, and impair endothelial function. Because the penile arteries are relatively small, subtle vascular dysfunction may become noticeable there before it causes symptoms in larger vessels.
This does not mean that every psoriasis flare directly produces erection difficulty. The relationship is more plausibly cumulative and systemic. Disease duration, inflammatory burden, smoking, blood pressure, glucose control, and lipid levels can combine to reduce vascular reserve. Some research has identified higher circulating endothelial adhesion markers in men who have both psoriasis and arteriogenic ED, supporting a biologically plausible vascular connection, although these markers are not routine clinical tests for erectile symptoms [5].
Inflammation may also interact with hormonal and neurologic pathways. Severe chronic illness can alter sleep, energy, mood, and sexual desire. These factors affect sexual response independently of penile blood flow and may amplify an underlying vascular limitation.
Shared Cardiometabolic Risk Factors
Psoriasis is associated with higher rates of obesity, insulin resistance, type 2 diabetes, hypertension, dyslipidemia, metabolic syndrome, and cardiovascular disease. Each is also an established risk factor for erectile dysfunction. This overlap makes it difficult to isolate the effect of psoriasis itself, but it also makes an ED evaluation especially valuable.
For example, diabetes can damage both small blood vessels and peripheral nerves. Hypertension increases mechanical stress on the endothelium, while some antihypertensive drugs may affect sexual function in susceptible men. Abdominal obesity is linked to inflammation, lower testosterone in some men, sleep apnea, and impaired vascular health. Smoking constricts blood vessels and accelerates atherosclerosis. The combined effect may matter more than any individual factor.
Erectile dysfunction can therefore function as a clinical prompt to assess cardiovascular risk. A reasonable evaluation may include blood pressure, fasting glucose or hemoglobin A1c, lipid testing, weight and waist measures, tobacco exposure, exercise patterns, and family history. Depending on symptoms, clinicians may also evaluate testosterone, thyroid function, sleep apnea, or medication effects.
Men should seek prompt medical care for ED accompanied by chest discomfort, shortness of breath with modest exertion, fainting, or other possible cardiovascular symptoms. Sexual activity itself imposes a cardiovascular workload, and treatment should be individualized when heart disease is unstable.
Skin Symptoms, Mood, and Sexual Confidence
Not all sexual dysfunction in psoriasis is vascular. Visible plaques, genital involvement, pain, itching, scaling, and concern about a partner's reaction can affect desire and confidence. Fatigue and joint pain from psoriatic arthritis may make intimacy uncomfortable. Depression and anxiety are also more common in chronic inflammatory disease and can reduce libido, impair arousal, and intensify performance anxiety.
This distinction matters because erectile function, desire, orgasm, and satisfaction are related but separate domains. A man may have normal nocturnal or solitary erections yet struggle during partnered sex because of pain, self-consciousness, or anticipatory anxiety. Another may have persistent difficulty across situations because arterial inflow is impaired. Many men have a mixture of organic and psychological contributors.
Clinicians can clarify the pattern by asking when symptoms began, whether erections occur during sleep or masturbation, whether desire has changed, and whether symptoms track with psoriasis flares or treatment changes. Genital psoriasis should be assessed directly because it may be missed if neither patient nor clinician raises the subject. Appropriate dermatologic treatment, counseling, couples therapy, or sex therapy may support recovery when discomfort or distress is central.
Diagnosis and Treatment Considerations
Evaluation usually begins with medical, medication, and sexual histories plus a focused physical examination. A validated questionnaire such as the five-item International Index of Erectile Function can help quantify severity and follow change over time. The goal is not merely to prescribe an erection medication; it is to identify reversible contributors and detect relevant vascular disease.
Psoriasis treatment should not be stopped or changed without the prescribing clinician. Available evidence does not show that systemic psoriasis therapy uniformly worsens male erectile function. Effective control of inflammation, pain, and visible disease may improve quality of life, but evidence that biologic therapy directly restores erections remains limited. Medication review should also cover antidepressants, opioids, antihypertensives, finasteride, recreational substances, and supplements.
Lifestyle measures can support both vascular and dermatologic health. Regular aerobic and resistance exercise, smoking cessation, adequate sleep, moderation of alcohol, and treatment of diabetes or hypertension may improve endothelial function. Sustainable weight reduction may help men with excess adiposity. These strategies are medically useful, but they should not be framed as a guaranteed cure for ED or psoriasis.
Phosphodiesterase type 5 inhibitors, including tadalafil, sildenafil, and vardenafil, enhance the nitric oxide–cGMP pathway and are established treatments for many forms of erectile dysfunction. They require sexual stimulation and do not directly treat psoriasis. Response may be reduced when vascular disease is advanced, dosing is incorrect, or anxiety and relationship factors predominate. Clinician supervision is essential because PDE5 inhibitors must not be used with nitrate medications and require caution with riociguat, some alpha-blockers, significant hypotension, unstable cardiovascular disease, and certain drug interactions.
When to Talk With a Clinician
Men should consider an evaluation when erection difficulty persists for several weeks, recurs frequently, or causes distress. Earlier discussion is particularly appropriate when psoriasis is moderate to severe, psoriatic arthritis is present, or cardiovascular risk factors are accumulating. Sudden ED may warrant prompt assessment, especially when accompanied by neurologic, endocrine, or cardiovascular symptoms.
A useful consultation covers three questions: Is the problem primarily vascular, hormonal, neurologic, medication-related, psychological, or mixed? Does it reveal a broader health risk that needs attention? Which treatment is safe given the individual's psoriasis therapy, cardiovascular status, and other medications? Answering those questions produces a more durable plan than treating the symptom in isolation.
Emergency care is appropriate for chest pain, fainting, or severe shortness of breath. Men using ED medication should also seek urgent care for sudden vision or hearing loss or an erection lasting longer than four hours.
Conclusion
Psoriasis and erectile dysfunction are linked in clinical research, but the relationship is not deterministic. Chronic inflammation may impair endothelial signaling, while cardiometabolic disease, skin discomfort, medication effects, mood, and sexual confidence can add to the burden. Persistent ED in a man with psoriasis should prompt a structured assessment of both sexual function and overall vascular health. Treating inflammation, addressing risk factors, and selecting evidence-based ED care may support better outcomes, but the appropriate combination varies by patient.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans, including EPIQ CHEWS, starting with a free online assessment at questionnaire.getonyxmd.com. Additional evidence-based men's health articles are available in the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Zhao S, Wang J, Xie Q, et al. High prevalence of erectile dysfunction in men with psoriasis: evidence from a systematic review and meta-analysis. International Journal of Impotence Research. 2019;31(1):74-84. doi:10.1038/s41443-018-0093-8
Egeberg A, Hansen PR, Gislason GH, Skov L, Thyssen JP. Erectile dysfunction in male adults with atopic dermatitis and psoriasis. The Journal of Sexual Medicine. 2017;14(3):380-386. doi:10.1016/j.jsxm.2016.12.233
Nowowiejska J, Karny A, Nesterowicz M, et al. Sexual dysfunctions in psoriatic patients. Frontiers in Public Health. 2024;12:1339196. doi:10.3389/fpubh.2024.1339196
Tanasov A, Tiplica GS. Erectile dysfunction in dermatology and venereology: from aetiopathogenic mechanisms to practical considerations for dermato-venereologists. Journal of the European Academy of Dermatology and Venereology. 2025;39:1725-1737. doi:10.1111/jdv.20618
Zayed A, Abd El-Aal E, Elshahed A, Ismail N. Serum level of endothelial markers in patients with psoriasis vulgaris with or without arteriogenic erectile dysfunction. Al-Azhar International Medical Journal. 2022;3(1):13-20. doi:10.21608/aimj.2022.95508.1572
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.